Post-IPO Momentum: Q1 Set to Extend FY26's Strong Growth Run
Lohia Corp, fresh off a July IPO at a 9% premium, reports Q1 FY-2027 results on August 19. With FY26's 25% revenue and 65% profit growth as backdrop, Street focus turns to whether the machinery exporter can sustain momentum and clarify full-year guidance in a thin-coverage environment.
The Setup
Lohia Corp, the technical textiles machinery leader that listed at ₹461 on July 30, 2026 (a 9% premium to the IPO price band), enters results season with momentum from a strong FY26. The company manufactures tape extrusion lines, circular looms, winders, coating machines, and recycling equipment for woven polypropylene and HDPE packaging — the unglamorous but resilient backbone of global flexible packaging. With a 40.7% share of India's woven raffia machinery market and exports to ~100 countries, the company is less dependent on domestic capex cycles than many peers. For Q1 FY-2027, the market will be watching whether this IPO newcomer can hold the 25% revenue and 65% profit growth posted in FY26, and what management has to say about full-year run-rate and guidance now that it's a public company.
What to Expect
~₹468–475 Cr
Assumes mid-20s% growth continuation; FY26 Q1 baseline not found in our DB, but FY26 full-year ₹1,738 Cr implies run-rate. Post-IPO capex/organic growth tracking.
~19–20%
FY26 margin at 19.53%; strong export mix and operating leverage expected to hold. Watch for any IPO-related capex drag.
~18–25% YoY
FY26 saw 65% jump to ₹193 Cr. Q1 likely normalizes after exceptional prior-year base; margins and tax rate key swing factors.
Watch for commentary
First quarterly call as a public company; Street will press on global demand, pipeline, and any macro headwinds in textiles capex.
Strong print: Revenue above ₹475 Cr with EBITDA margin holding 19.5%+ and management guiding for 15%+ full-year growth. Visibility into near-term order flow and no margin compression signals confidence in sustained export demand. Weak print: Revenue below ₹450 Cr, margin decline below 18.5%, or cautious guidance on H2 demand. Any commentary on rising input costs, forex headwinds, or softening global capex would be a red flag for a company this export-heavy.
On Track?
FY26 delivered stunning growth — 25% revenue, 65% PAT — but this was a post-pandemic recovery baseline. No prior-quarter standalone P&L is in our DB to confirm sequential tracking. The Board will have finalized FY27 targets and capex plans pre-listing; investors will want clarity on whether management believes FY26's growth rate is repeatable (likely not at 65% PAT, but 15–20% would be solid for a capital-goods exporter). Key: is the company guiding for a normalized full-year, or suggesting this IPO capital goes into capacity that accelerates H2 momentum?
What the Street Says
Since Last Quarter
Jul 30, 2026
Window closed for designated persons & kin; effective until 48 hours post-result announcement.
Trading Window Closure
Jul 30, 2026
Shares listed at ₹461, a 9% premium to the ₹404–425 price band. Raised ₹1,101 Cr.
IPO Listing
Aug 12, 2026
Board to convene Aug 19 to approve Q1 FY-2027 unaudited standalone and consolidated financials.
Board Meeting Notice
Bulk/Block Activity: Over the last ~6 months, a pattern of matched pairs emerged (NK Securities, Jump Trading, Microcurves), each pair roughly matched buy/sell at similar prices (₹487–494), suggesting algorithmic/index rebalancing or short-term positioning rather than strategic stake-building. No promoter insider buying or selling flagged — the 68.66% promoter stake (as of Q2 FY27 filing) remains unchanged. Trading window closure is routine pre-result protocol.
What to Watch on Result Day
1 · Revenue & margin run-rate
Does Q1 confirm the 25% growth from FY26 is a floor (normalizing from recovery) or a ceiling? EBITDA margin at or above 19.5% matters for valuation anchoring in an IPO-to-ratings phase.
2 · FY27 guidance & commentary
First public call; Street will press management on full-year expectations, capex deployment, and how macro textiles capex and forex shifts affect demand. Any geo-concentration risk (% of revenue by region) is new-IPO standard query.
3 · Order book depth
How much of expected FY27 is already booked? Visibility into near-term export orders is critical for a capital-goods player. Softness here suggests demand concerns ahead.
4 · Margin expansion or pressure
Rising input costs or shipping fees could pressure the 19.5% EBITDA margin. Management's narrative on pricing power vs. cost pass-through will shape investor sentiment on sustained profitability.
Lohia Corp's post-IPO debut lands as a textiles-machinery play with proven export credentials and 40%+ domestic market share. Q1 results will set the tone for whether FY26's growth is sustainable or a recovery blip. With zero analyst coverage and no forward consensus, the company's own guidance will be the market's first real signal. A result that confirms 20%+ revenue growth and stable-to-expanding margins keeps IPO momentum alive; a miss or cautious commentary resets valuations sharply downward in an overcrowded capex narrative.
Record Order Book Masks Domestic Revenue Shift; Execution Risk Ahead
₹1,778 Cr order book (195% YoY) and strong P&L beat are real, but 70% domestic composition vs. 59% revenue share creates a margin hedging game. Management is confident on pre-booked prices; the market should watch execution.
₹503 Cr
+60% YoY
₹100 Cr
19.9% margin
₹66.3 Cr
+289% YoY
₹1,778 Cr
+195% YoY
~70%
vs 59% revenue
6–9 months
backend loading risk
The quarter is a paradox: a headline print that beats and an order book that impresses, shadowed by a single uncomfortable fact. Of ₹1,778 crore in orders, 70% is now domestic—but domestic was only 59% of Q1 revenue. That gap is management's problem, not Lohia's business problem. The company is hedging margins via pre-booked order prices, claiming a 15–20% premium over China still holds. The street bought it halfway. The question is whether six to nine months of execution closes the game or opens it.
The delivered result: no reconciliation needed
Unlike some this season, there is no MTM gain, no tax beat, no exceptional item inflating reported profit. Revenue of ₹503 crore (+60% YoY) and PAT of ₹66.3 crore (+289% YoY) are organic. EBITDA of ₹100 crore sits at 19.9% margin—matching the company's pre-COVID 15–20% band and Q4 FY26 performance. What you see is what happened: capacity utilization at 70–72%, order book hedging domestic mix risk, and operating leverage flowing through. No asterisk.
The PAT jump is steep because Q1 FY26 was compressed (₹17 crore, 2.7% NPM). The 289% YoY is real but not a step-change; it is operating leverage on a recovery base. The number to anchor on is the 13% net profit margin—healthy and stable.
Management's claims: what holds up, what doesn't
EBITDA ₹100 Cr at 19.9% margin
SupportedDelivered: ₹100 Cr EBITDA, 19.9% OPM. Pre-COVID range 15–20% confirmed.
20% EBITDA margins sustainable going forward
SupportedQ1 FY27: 19.9%. Q4 FY26: 11.5% (lower mix). Pre-COVID norm 15–20% re-established.
Order book ₹1,778 Cr
VerifiedVerified at end Q1 FY27. 195% YoY growth. 3–4 quarters of revenue visibility at 6–9M execution.
Exports will revert to 45–55% of revenue going forward
OverstatedCurrently 41% of Q1 revenue. Only 30% of order book. No quantified timeline. Historical range cited but not projected for when.
Domestic order book won't hurt margins due to pre-booked order prices
PartialDomestic 70% of ₹1,778 Cr orders vs 59% of Q1 revenue. Management cites price discipline and pre-booked hedges; no structural margin improvement.
20% margin 'internally targeted' going forward
HedgedStated as target, not formal guidance. Cautious language; concedes geopolitical, commodity, and mix headwinds.
What changed on this call
Order book composition shifted to 70% domestic. Historically Lohia was 41–55% exports. Post-COVID domestic expansion capex is driving the shift. Margins depend on pre-booked order prices holding.
Capacity runway clarified. 70–72% utilization today, 85% peak. Turnover can reach ₹2,400–2,500 Cr without major capex; capex only beyond that (5–6 month deployment window when approved).
Margin guidance formalized—but cautiously. Not a committed target; stated as 'internally target 20%'. Concedes geopolitical, raw material, and competitive headwinds.
Non-packaging applications rising. FIBC, technical textiles, geotextiles picking up. Single-use plastic ban driving substitution. Diversifies end-market beyond woven bags.
The bull case
Order book visibility is real. ₹1,778 crore is 3–4 quarters of revenue at 6–9 month execution. At ₹503 crore quarterly run-rate, this book covers H2 FY27 and into FY28. Capex expansion in cement, FIBC, and technical textiles is structural, not cyclical. The single-use plastic ban is a tailwind for at least 3–5 years.
Margins are hedged, not compressed. Management has 2,000 customers globally and only 2–3 known competing suppliers worldwide. The 15–20% premium over China is defensible on service, reliability, and 25 years of export relationships. Pre-booked order prices mean Q1–Q2 domestic revenue is already priced; the risk is Q3–Q4 orders repricing lower.
Replacement cycle is in the early innings. Machines sold in 2002–2003 are now 22–24 years old globally. Currently replacement is only 3–5% of order book; as aging machines fail, this should accelerate. Management is unquantified on this, but it is a multi-year tail upside.
The bear case
Domestic order concentration could compress margins if repricing stalls. 70% of ₹1,778 crore in orders is domestic (roughly ₹1,245 crore). If customer negotiations push back on prices in Q3–Q4, or if new orders land at lower margin, the 19.9% could drop to 15–17% within two quarters. Management's confidence in pre-booked prices is not quantified.
Export reversion is an assumption, not a plan. The company believes exports will return to 45–55% of revenue, but order book shows only 30%. The gap is roughly ₹530 crore in unbooked export sales (if reversion to 50% is to hold). No timeline, no customer pipeline detail. If geopolitical instability or Chinese competition deepens, this reversion delays and domestic dominance lingers, dragging margins.
Execution risk on 6–9 month cycles is real. Order book visibility is high, but backend-loaded delivery (Q3–Q4 FY27 concentration) means revenue timing concentration. Any supply chain slip, customer capex delay, or credit issue could push deliveries into FY28, flattening H2 FY27 revenue and delaying cash conversion.
Geopolitical and commodity headwinds are acknowledged but uncontrollable. Management cited wars, China supply decisions, and raw material movement as margin headwinds multiple times. If inflation accelerates or supply disruption persists, margins compress despite pre-booked orders (commodity pass-through delays are real).
How the street is positioned
The market's initial reaction was skeptical: the stock fell 3.82% on day 1 post-announcement, with 49.2% delivery, suggesting retail selling pressure. By day 3, however, sentiment shifted: +4.06% recovery. By day 5, the stock was +6.57% from the announcement close of ₹561.3, pricing in acceptance of the order book bull case. The recovery suggests the market is now betting on execution.
Ownership is dominated by promoters (68.66%), with DII meaningful at 17.52% and FII light at 5.65%. The low FII holding suggests foreign money is cautious; DII strength indicates domestic institutional conviction. Bulk and block deals in the last six months show trading (buys and sells in the ₹487–494 range), with no promoter insider selling near highs—a clean signal.
The recovery from day 1 to day 5 (+6.57%) is the market's own verdict: the order book story is real, execution risk is priced in at current levels, and domestic margin hedging is credible enough to own. The street is not overheated but is comfortable.
Risks ranked by severity for a holder
Domestic order repricing to lower margin in Q3–Q4
High70% of order book is domestic. If customer pushback on price occurs, EBITDA margin could compress from 19.9% to 15–17%, killing the bull case. Pre-booked hedge is claimed but not quantified.
Order execution timeline slips (backend loading into FY28)
Medium6–9 month cycles mean Q3–Q4 FY27 revenue concentration. A supply chain slip or customer capex delay pushes deliveries out, flattening H2 revenue and cash conversion. Valuation assumes order visibility; timing miss hurts credibility.
Export reversion delays (remains <30% of order book)
MediumCompany expects exports to revert to 50% of revenue, but order book shows only 30%. If geopolitical or Chinese competition pressure persists, export orders remain weak, domestic concentration stays high, and margin hedging becomes the permanent story (not a transition).
Commodity inflation or supply disruption unwinds margins despite pre-booked orders
MediumRaw material pass-through has lags. If inflation accelerates post-order booking, pre-booked order margins compress. Management conceded this multiple times on the call.
Chinese competitor premium erosion in a macro slowdown
Low15–20% premium over China is assumed. If demand weakens globally, customers pivot to cheaper. Service moat is real but not immunity.
The debate
1 · Q2 FY27: Order execution ramp and domestic revenue margin
Does EBITDA stay at 19.9% or slip to 15–17%? This is the margin hedge in action. Watch gross margin (commodity pass-through) and SG&A (operating leverage). Execution on the order book should accelerate in Q2–Q3.
2 · Export order progression in H2 FY27
Order book shows 30% export; management expects 50%. Watch quarterly order inflow for export uptick. If exports stay weak, the domestic concentration risk becomes structural.
3 · Replacement cycle first signals (Q3–Q4)
Currently only 3–5% of orders. Watch for management language on aging machine replacement in developed markets and India. Quantification of this opportunity will unlock a multi-year re-rating.
4 · Guidance revision
If margins hold at 19.9% or expand to 20%+ by Q3, expect management to formalize guidance beyond 'internally targeted'. Conversely, if Q2–Q3 see margin compression, the 20% target gets quietly abandoned.
Lohia Corp is not a step-change quarter—it is steady execution on a strong order book, shadowed by a single bet: that pre-booked domestic order prices hold through Q4 FY27. The company is technically excellent (2,000 customers, only 2–3 known competitors globally, 25-year export relationships). The order book is massive (₹1,778 Cr, 195% YoY). Margins are hedged, not guaranteed.
The stock's recovery from day 1 to day 5 (+6.57%) tells you the street believes the order book and accepts the execution risk. The real test is Q2: if domestic revenue margins hold at 19.9% or expand, the story is intact and export reversion becomes the next narrative. If margins slip to 15–17%, the domestic concentration risk becomes real and the bull case cracks.
Hold and watch Q2. The number to track is EBITDA margin—everything else is noise.
Lohia Corp Q1FY27: consol PAT +292% YoY to ₹66 Cr, revenue +60%, margins expand sharply
PAT +292.4% YoY · revenue +59.5% · margins expanding
₹503.02 Cr
+59.5% YoY
₹66.26 Cr
+292.4% YoY
13%
₹6.27
Lohia Corp's first results as a listed company show consolidated revenue of ₹503 Cr, up 59.5% YoY (down a marginal 1.5% QoQ from ₹511 Cr in Q4FY26), with consolidated PAT of ₹66.3 Cr, up 292% YoY (down 7.3% QoQ from ₹71.5 Cr). Standalone — the entity our pre-result preview benchmarked — did even better: revenue of ₹500 Cr (+63.3% YoY) and PAT of ₹73.3 Cr (+317% YoY), both comfortably ahead of our preview's on-plan range of ₹468-475 Cr revenue and 18-25% YoY PAT growth. No exceptional items hit either statement this quarter, so the beat is clean, not one-off driven.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
The re-rating is a margin story: consolidated EBITDA margin (PBT before exceptional items + depreciation + finance cost, over revenue) expanded to ~21.2% from ~12.7% a year ago, and net margin to 13.2% from 5.4%, as employee costs fell to 10.6% of revenue from 15.0% and other expenses to 13.8% from 16.8% — classic operating leverage on the 60%+ topline surge rather than any cost cut. Sequentially the margin cooled slightly (22.1% in Q4FY26 to 21.2% now), so YoY is the real signal, not the modest QoQ dip.
What the summary numbers don't show
EPS ₹6.27 consolidated / ₹6.94 standalone vs ₹1.60 / ₹1.66 a year ago
No exceptional items this quarter, unlike FY26 (₹9.4 Cr labour-code + ₹1.4 Cr Leesona impairment charges)
Street context is thin by design: our preview flagged zero analyst estimates for this quarter given the recent IPO, and a web search today turned up no formal consensus either — vsStreet stays unknown rather than guessed. The quarter itself predates the listing: Lohia completed a ₹1,101 Cr offer-for-sale IPO at ₹425/share and listed on NSE/BSE on 30 July 2026, after closing its insider trading window on 31 July. Standalone PAT (₹73.3 Cr) ran ahead of consolidated (₹66.3 Cr) because six overseas subsidiaries, including Leesona Corp USA, posted a combined net loss of ₹5.6 Cr on ₹25.1 Cr revenue this quarter — a drag flagged separately by the joint auditor. Management issued no accompanying press release with this filing; a Motilal Oswal-hosted earnings call (reported for 20 August) will be the company's first as a listed entity and the first venue for formal FY27 guidance and order-book commentary, neither of which is disclosed in this filing.
W1
First post-listing earnings call (reported 20 Aug) for formal FY27 guidance — none on record yet
W2
Whether ~21% consolidated EBITDA margin holds or reverts toward the 22.1% Q4FY26 / 12.7% Q1FY26 range
W3
Overseas subsidiary losses (₹5.6 Cr this quarter) — watch for a turn to profitability at Leesona and other international units
Clean text-based PDF, both statements tie exactly (total income = revenue+other income; PAT = PBT-tax). No exceptional items in current or year-ago quarter (FY26 had ₹9.4 Cr labour-code + ₹1.4 Cr Leesona impairment exceptionals, none in Q1FY27). Consolidated PAT of ₹66.3 Cr includes NCI loss of ₹0.35 Cr; PAT attributable to owners is ₹66.6 Cr. Six overseas subsidiaries (incl. Leesona Corp USA) posted combined net loss ₹5.6 Cr on ₹25.1 Cr revenue this quarter per auditor note.
Strong order book growth masks domestic revenue mix shift; margins held via pre-booked orders
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
First call post-IPO; delivered numbers match stated results. Pre-COVID guidance (15-20% margins) confirmed in execution (19.9% Q1, 11.5% Q4). No prior numeric guidance to miss.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong order book visibility (₹1,778 Cr, 195% YoY growth) and delivered Q1 beat on revenue/PAT support the bullish case. However, execution risk (6-9 month cycles) and domestic revenue mix shift (70% of orders, only 59% of Q1 revenue) create near-term margin pressure that management is hedging rather than affirming. Hold until execution trajectory clears.
₹503 Cr
Revenue · +60% YoY₹66.3 Cr
Reported PAT · +289.4% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
EBITDA ₹100 Cr at 19.9% margin
METEBITDA ₹100 Cr (verified); OPM 19.9% matches reported
20% EBITDA margins sustainable going forward
METAchieved 19.9% in Q1 and 11.5% in Q1 FY26; pre-COVID range 15-20%
Order book ₹1,778 Cr up 30% since March 26
METVerified ₹1,778 Cr at end Q1 FY27; growth trajectory consistent
Exports revert to 50% of revenue going forward
OVERSTATEDCurrently 41% of Q1 revenue; order book only 30% export. Assertion not yet evidenced
Domestic order book won't hurt margins due to pre-booked prices
PartialDomestic now 70% of order book but only 59% of Q1 revenue—hedging on price contracts
Earnings quality
What changed since the last call
Order book composition shift
DowngradeDomestic orders 70% of ₹1,778 Cr vs historical 41-50% exports. Margin impact hedged but not eliminated.
Capacity utilization clarity
UpgradeDisclosed 70-72% current vs prior ambiguity. Runway to 85% and ₹2,500 Cr without major capex confirmed.
Margin guidance formalized
NeutralPre-COVID 15-20% range re-confirmed; 20% 'internally targeted', not formal. Cautious vs bullish framing.
The Q&A
Analysts pressed hard on margin sustainability (Harshit, Shreyansh), domestic mix headwind (Shreyansh), and order book peak risk (Kiran). Management held line on 20% margins via price discipline and pre-booked orders but did not boldly commit—caveats on geopolitics, raw material, competition conceded.
Order book composition — Kiran, Table Tree
AnsweredPost-COVID investment recovery; non-packaging applications rising; single-use plastic ban driving demand. Not peak; peak yet to come.
Export margin sustainability — Shreyansh Talesara, Equentis
PartialOperating leverage will play out; in export-heavy years EBITDA inches up; internally target 20%, no forward guidance.
Capacity runway — Akshay Satija, Alpha Invesco
Answered80-85% peak; current ₹503 Cr at ~70% utilization suggests runway. Major capex needed beyond ₹2,500 Cr, not immediately planned.
Margin drivers — Harshit Patel, Equirus
AnsweredPrice revision per order; short/medium-term supplier contracts; discount structure tweaks. Three-pronged approach.
Chinese competition — Shivam Gupta, Trinetra
AnsweredYes, 15-20% premium due to service, reliability. China weak on service; India harder for them to break export.
Growth vs customer capex — Rishi Maheshwari, Aksa
AnsweredTechnical barrier in machine manufacturing. We have 2,000 customers globally; only 2-3 known suppliers worldwide.
R&D and new products — Arvind Arora, A Square
Partial3% to remain average. Confidential automation/IoT developments underway. 3% maintained going forward.
Replacement cycle — Prince Choudhary, Pinc Wealth
PartialMajority expansion (new). 3-5% replacement. Globally, 25 years of exports now hitting replacement. Quantification difficult.
Guidance
FY27 revenue growth 20-25% range
MediumBased on rising non-packaging applications and customer capex expansion. Order book ₹1,778 Cr supports base.
EBITDA margin 20% internally targeted
MediumNot formal guidance; achieved in Q1 FY27 (19.9%) and Q4 FY26 (11.5% stated as comparison). Pre-COVID norm 15-20%.
Major capex only beyond ₹2,500 Cr turnover
HighCurrent ₹503 Cr at 70% utilization can grow to ₹2,400-2,500 Cr. Capex deployment 5-6 months once approved.
Risks the call surfaced
Order execution timing
Medium₹1,778 Cr order book executed over 6-9 months means backend loading. Q2-Q3 ramp-up execution risk.
Domestic revenue concentration
Medium70% of order book now domestic vs 59% of Q1 revenue. If domestic margin lower and repricing delayed, margins compress.
Export order recovery delay
MediumManagement expects exports to revert to 45-55% (50%) of revenue, but currently only 30% of order book. Timing unclear.
Geopolitical & commodity volatility
MediumManagement cited wars, China supply decisions, raw material movement as margin headwinds. Macro uncertainty not controllable.
Chinese competition and pricing power
Low15-20% premium over China maintained today, but if downturn arrives, premium could compress.
Management
Score 7/10. Transparent on challenges (domestic mix shift, geopolitical risks, margin hedging) but cautious on forward commitments. Pre-IPO listing first call shows discipline. Delivered Q1 results match stated numbers exactly. Order book growth sustained (195% YoY) and operational improvements (EBITDA +276%) executed.
1 · Q2 FY27
Order execution ramp; domestic mix revenue impact on margins
2 · H2 FY27
Export order book reversal from 30% to 50% (if management thesis holds)
3 · FY28
Capacity expansion capex (₹80-100 Cr) if revenue hits ₹2,500 Cr
Hold until execution trajectory clears.